Vertebrobasilar Insufficiency is also called beauty parlor syndrome. It is defined as the temporaty decrease of blood flow in the posterior circulation of the brain. The most common symptoms are vertigo, dizziness, headaches, vomiting, ataxia, and weakness in both sides of the body. The main risk factors associated with vertebrobasilar insufficiency are arterial hypertension, obesity, and smoking.
Vertebrobasilar Insufficiency Treatment Market contains market size and forecasts of Vertebrobasilar Insufficiency Treatment in Global, including the following market information:
- Global Vertebrobasilar Insufficiency Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Vertebrobasilar Insufficiency Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
- The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
- Antihistamine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
- The global key manufacturers of Vertebrobasilar Insufficiency Treatment include Novartis, AstraZeneca plc, Intas Pharmaceutical Ltd, Cadila Pharmaceuticals, Pfizer Inc, Sanofi S.A, Medichem S.A, Abbott Pharmaceuticals and LGM Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
- We surveyed the Vertebrobasilar Insufficiency Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Vertebrobasilar Insufficiency Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Vertebrobasilar Insufficiency Treatment Market Segment Percentages, by Type, 2021 (%)
- Antihistamine
- Anticholinergic
- Antiplatelet agents
- Vasodilators
Global Vertebrobasilar Insufficiency Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Vertebrobasilar Insufficiency Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Vertebrobasilar Insufficiency Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Vertebrobasilar Insufficiency Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Vertebrobasilar Insufficiency Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Vertebrobasilar Insufficiency Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Novartis
- AstraZeneca plc
- Intas Pharmaceutical Ltd
- Cadila Pharmaceuticals
- Pfizer Inc
- Sanofi S.A
- Medichem S.A
- Abbott Pharmaceuticals
- LGM Pharma
- Sun Pharmaceutical Industries Ltd
Industry Market Size
